Royal Bank of Canada reiterated their outperform rating on shares of Immune Design (NASDAQ:IMDZ) in a research report report published on Friday morning, The Fly reports. Royal Bank of Canada currently has a $11.00 target price on the biotechnology company’s stock.
A number of other research analysts have also weighed in on IMDZ. Zacks Investment Research lowered shares of Immune Design from a buy rating to a sell rating in a research note on Wednesday, July 4th. Leerink Swann lowered shares of Immune Design from an outperform rating to a market perform rating in a research note on Friday. Finally, HC Wainwright assumed coverage on shares of Immune Design in a research note on Wednesday, August 29th. They issued a buy rating and a $11.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $8.40.
Immune Design stock traded down $0.94 during midday trading on Friday, reaching $1.85. The company had a trading volume of 3,329,086 shares, compared to its average volume of 342,327. The firm has a market capitalization of $166.17 million, a PE ratio of -1.06 and a beta of 1.77. Immune Design has a 12-month low of $1.47 and a 12-month high of $11.05.
Immune Design (NASDAQ:IMDZ) last issued its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.01. The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.64 million. Immune Design had a negative net margin of 2,324.21% and a negative return on equity of 46.95%. On average, equities analysts anticipate that Immune Design will post -1.25 EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the stock. DRW Securities LLC lifted its stake in Immune Design by 59.2% in the 2nd quarter. DRW Securities LLC now owns 58,900 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 21,900 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Immune Design by 456.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 192,330 shares of the biotechnology company’s stock worth $635,000 after purchasing an additional 157,784 shares in the last quarter. Alps Advisors Inc. purchased a new position in Immune Design in the 2nd quarter worth approximately $318,000. Portolan Capital Management LLC purchased a new position in Immune Design in the 2nd quarter worth approximately $2,024,000. Finally, BlackRock Inc. lifted its stake in Immune Design by 2.6% in the 1st quarter. BlackRock Inc. now owns 1,917,100 shares of the biotechnology company’s stock worth $6,326,000 after purchasing an additional 49,022 shares in the last quarter. 49.41% of the stock is currently owned by hedge funds and other institutional investors.
About Immune Design
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Recommended Story: How to Invest in Growth Stocks
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.